Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs Abatacept in Active Rheumatoid Arthritis
NCT01350804Phase 3Completed
- Sponsor
- Novartis
- Start
- Sep 2011
- Primary completion
- Feb 2015
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
Phase 3, randomised, double-blind trial of secukinumab in rheumatoid arthritis (RA) (4 arms), sponsored by Novartis. Primary endpoint: Percentage of Participants Achieving an American College of Rheumatology Response 20 at 24 weeks. Started Sep 2011; status: completed.
02
Drugs
secukinumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT01350804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350804.